» Articles » PMID: 26020387

Higher Risk of Myasthenia Gravis in Patients with Thyroid and Allergic Diseases: a National Population-based Study

Overview
Specialty General Medicine
Date 2015 May 29
PMID 26020387
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to determine the risk of myasthenia gravis (MG) in patients with allergic or autoimmune thyroid disease in a large cohort representing 99% of the population in Taiwan. Data from the Taiwan National Health Insurance Database were used to conduct retrospective analyses. The study comprised 1689 adult patients with MG who were 4-fold frequency matched to those without MG by sex, age, and assigned the same index year. Multivariate logistic regression models were used to calculate the odds ratios and 95% confidence intervals for the association between allergic or autoimmune thyroid disease and MG. An increased subsequent risk of MG was observed in the patients with allergic conjunctivitis (AC), allergic rhinitis, Hashimoto thyroiditis, and Graves disease. The adjusted odds ratios (aORs) were 1.93 (1.71-2.18), 1.26 (1.09-1.45), 2.87 (1.18-6.97), and 3.97 (2.71-5.83), respectively. The aORs increased from 1.63 (1.43-1.85) in a patient with only 1 allergic or autoimmune thyroid disease to 2.09 (1.75-2.49) in a patient with 2 thyroid or allergic diseases to 2.82 (2.19-3.64) in a patient with ≥3 thyroid or allergic diseases. MG was associated with the cumulative effect of concurrent allergic and autoimmune thyroid disease with combined AC and Hashimoto thyroiditis representing the highest risk (aOR = 15.62 [2.88-87.71]). This population-based case-control study demonstrates the association between allergic or autoimmune thyroid disease and the risk of MG. The highest risk of subsequent MG was associated with combined AC and Hashimoto thyroiditis.

Citing Articles

Diabetes mellitus in patients with myasthenia gravis: a systematic review and meta-analysis.

Shao T, Lu J, Kang H, Zhang Y, Lan T, Wang J Endocrine. 2024; .

PMID: 39729181 DOI: 10.1007/s12020-024-04143-1.


Autoimmune thyroid disease and myasthenia gravis: a study bidirectional Mendelian randomization.

Wang S, Wang K, Chen X, Chen D, Lin S Front Endocrinol (Lausanne). 2024; 15:1310083.

PMID: 38405140 PMC: 10884276. DOI: 10.3389/fendo.2024.1310083.


Myasthenia gravis and five autoimmune diseases: a bidirectional Mendelian randomization study.

Li K, Ouyang Y, Yang H Neurol Sci. 2023; 45(4):1699-1706.

PMID: 37910321 DOI: 10.1007/s10072-023-07163-3.


LncRNA GAS5 positively regulates IL-10 expression in patients with generalized myasthenia gravis.

Peng S, Huang Y Brain Behav. 2021; 12(1):e2457.

PMID: 34936242 PMC: 8785628. DOI: 10.1002/brb3.2457.


Thymus pathology in myasthenia gravis with anti-acetylcholine receptor antibodies and concomitant Hashimoto's thyroiditis. A four-case series and literature review.

Ionescu L, Costea C, Danila R, Bogdanici C, Scripcariu D, Livadariu R Rom J Morphol Embryol. 2021; 62(1):73-83.

PMID: 34609410 PMC: 8597376. DOI: 10.47162/RJME.62.1.07.


References
1.
Conrad D, Ford J, Sturgill J, Gibb D . CD23: an overlooked regulator of allergic disease. Curr Allergy Asthma Rep. 2007; 7(5):331-7. DOI: 10.1007/s11882-007-0050-y. View

2.
Chen Y, Yeh J, Chiu H . Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand. 2012; 127(3):170-4. DOI: 10.1111/j.1600-0404.2012.01693.x. View

3.
Yeh J, Lin C, Chen Y, Sung F, Chiu H, Kao C . Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: a population-based cohort study. Neuromuscul Disord. 2013; 24(3):245-9. DOI: 10.1016/j.nmd.2013.11.007. View

4.
Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A . Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012; 129(5):1307-13. DOI: 10.1016/j.jaci.2012.01.043. View

5.
Gangemi S, Saitta S, Lombardo G, Patafi M, Benvenga S . Serum thyroid autoantibodies in patients with idiopathic either acute or chronic urticaria. J Endocrinol Invest. 2009; 32(2):107-10. DOI: 10.1007/BF03345696. View